Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of intravesical instillation of EO9 in patients with non-muscle invasive bladder cancer (NMIBC).
Bladder Cancer
DRUG: EO9(Apaziquone)
Safety assessment based on all Adverse events(causal relationship, incidence, severity, etc.), 14 weeks
pharmacokinetics assessment of EO9 and it's metabolites in blood and urine, before, 30, 55, 90 mins of EO9 instillation
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of intravesical instillation of EO9 in patients with non-muscle invasive bladder cancer (NMIBC).